What is Invirsa?
Invirsa is a biotechnology company dedicated to pioneering novel treatments for ocular conditions stemming from DNA damage. Their lead compound, INV-102, is engineered to address severe conditions such as ocular injuries caused by sulfur mustard gas and advanced diabetic dry eye. The company's strategic partnership with BARDA is instrumental in propelling the development of INV-102, with a clear objective to deliver disease-modifying therapies. Invirsa's approach is characterized by its innovative drug development methodology, aimed at overcoming substantial pharmaceutical hurdles and offering more than just symptomatic relief.
How much funding has Invirsa raised?
Invirsa has raised a total of $10.5M across 2 funding rounds:
Series B
$7.7M
Private Equity
$2.8M
Series B (2023): $7.7M with participation from Jumpstart Ventures, CincyTech, and Rev1 Ventures' Companies
Private Equity (2025): $2.8M, investors not publicly disclosed
Key Investors in Invirsa
Jumpstart Ventures
Jumpstart Ventures is an entity focused on providing learning opportunities for young entrepreneurs and connecting them to a supportive ecosystem of related services.
CincyTech
CincyTech, based in Cincinnati, Ohio, operates as a public-private seed-stage investor specializing in sectors such as enterprise software, business software applications, life sciences, and digital health.
Rev1 Ventures' Companies
Rev1 Ventures is a venture development studio in Columbus, Ohio, that provides seed-stage venture capital, startup services, and mentoring, having supported over 150 startups and invested in more than 300 companies to foster high-growth businesses.
What's next for Invirsa?
With the recent major strategic investment, Invirsa is poised for accelerated growth and the advancement of its therapeutic candidates. The enterprise-level funding suggests a strong validation of the company's technology and market potential, likely enabling Invirsa to expand its research and development efforts, potentially initiate clinical trials, and scale its operations. This strategic capital injection is expected to fortify its position in the competitive biotechnology landscape, particularly in the niche of ocular disease treatment.
See full Invirsa company page
